1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.2.1. Currency
1.2.2. Limitations
1.3. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Advancement in Ultrasound Technologies
4.2.1.1.1. Evolution of Microbubbles
4.2.1.1.2. Miniaturization of Ultrasound Devices
4.2.1.1.2.1. Wearable Ultrasound Pain therapy Device
4.2.1.1.2.2. Flow Focusing Microfluidic Devices (FFMDs)
4.2.1.1.2.3. Handheld Ultrasound Scanners
4.2.1.1.2.4. Phone-Based Ultrasound Systems
4.2.1.2. Benefits over Alternative Technologies
4.2.1.3. Favorable Reimbursement Policies for Ultrasound Contrast Enhanced
Procedures in the U.S.
4.2.1.4. Increase in Demand for Diagnostics & Image Guided Procedures influencing
the Sales of Microbubbles
4.2.1.5. Growing Aging Population and Subsequent Rise in the Prevalence of
Chronic Diseases
4.2.2. Restraints
4.2.2.1. Complexity involved in Conducting Contrast Enhanced
Ultrasound (CEUS) Procedures
4.2.3. Opportunities
4.2.3.1. Rising Microbubbles/ Ultrasound Contrast Agents Related Research
4.2.4. Trends
4.2.4.1. Expansion- A Key Growth Strategy Adopted by Market Players
5. Microbubbles/Ultrasound Contrast Agents Market, by Therapeutic Area
5.1. Introduction
5.2. Cardiovascular Diseases
5.2.1. Drivers
5.2.1.1. High incidence of Stroke Worldwide
5.2.1.2. Improvisation in therapies to Boost the Application in Sonothrombolysis
5.2.2. Sonothrombolysis: Future Potential
5.2.2.1. Prospects: Targeted Microbubbles
5.2.2.2. Prospects: Gene Delivery
5.3. Renal and Associated Diseases
5.3.1. Ultrasound Applications in Kidney
5.3.1.1. Diagnosis between Solid Renal Masses and Pseudo-Tumors
5.3.1.2. Differentiation between Cystic and Solid Lesions of the Kidneys
5.3.1.3. Characterization of Complex Cystic Renal Masses
5.3.1.4. Renal infections
5.3.1.5. Renal Trauma
5.3.1.6. Renal Artery Stenosis
5.3.1.7. Assessment of Percutaneous Ablation therapy
5.3.1.8. Kidney Transplantation
5.3.1.9. Kidney Fibrosis
5.3.2. Drivers
5.3.2.1. Regulatory Changes and Government Support to Boost Clinical Research Related to Kidney
5.3.3. Restraints
5.3.3.1. Retention of Microbubbles
5.4. Other Diseases
6. Microbubbles/Ultrasound Contrast Agents Market, by Application
6.1. Introduction
6.2. Molecular Imaging
6.2.1. Applications
6.2.2. Trends
6.2.2.1. Development of Novel Microbubbles to Improve Target Binding
6.2.2.2. Development of Novel Microbubbles to Suit the Modalities Used in Imaging
6.2.3. Challenges
6.2.3.1. Currently Ultrasound Molecular Imaging Is Still in Its infancy and Some Challenges Exist
6.3. Gene therapy
6.3.1. Drivers
6.3.2. Methods of Gene therapy
6.4. Drug Delivery
6.4.1. Drivers
6.4.1.1. Growing Number of Researchers in the Field of Drug Delivery Using Microbubbles
6.4.1.2. Rising incidence & Mortality of Cancer & Cardiac Disease to Create Need for Better Drug therapies
6.4.1.3. Growing Researches involving Targeted Drug Delivery Using Microbubbles
6.5. Stem Cell Delivery
6.5.1. Growing Researches
7. Microbubbles/Ultrasound Contrast Agents Market, by Geography
7.1. Introduction
7.2. North America
7.3. Europe
7.4. Asia-Pacific
7.5. Rest of the World
8. Competitive Landscape
8.1. Introduction
8.2. Approvals
8.3. Partnerships, Agreements, and Collaborations
8.4. Expansions & Others
9. Company Profiles(Business overview, Financial overview, Product Portfolio, Strategic Developments)
9.1. Lantheus Holdings, Inc.
9.2. Bracco
9.3. GE Healthcare
9.4. Daiichi Sankyo Company, Limited
9.5. nanoPET Pharma GmbH
10. Appendix
10.1. Questionnaire
10.2. Available Customization
List of Tables
Table 1 Global Microbubbles/Ultrasound Contrast Agents Market Drivers: Impact Analysis (2018-2024)
Table 2 Publications Related to Custom Microbubbles
Table 3 Comparison of Ultrasound Technologies over Other Technologies
Table 4 Medicare Payment for Contrast Enhanced Procedures (2016-2017)
Table 5 Global Microbubbles/Ultrasound Contrast Agents Market Restraints: Impact Analysis (2018-2024)
Table 6 List of Approved Microbubbles/Ultrasound Contrast Agents
Table 7 Global Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
Table 8 Potentially Accessible Targets for Molecular Imaging with Ultrasound
Table 9 Global Microbubbles/Ultrasound Contrast Agents Market Size for Cardiovascular Diseases, by Region, 2016-2024 (USD Million)
Table 10 Behavior of Microbubbles in Kidney
Table 11 Comparison of the Pathological Entities on Baseline Ultrasound and CEUS
Table 12 Researches Related to Microbubbles Mediated Renal therapies
Table 13 Global Microbubbles/Ultrasound Contrast Agents Market Size for Renal & Associated Diseases, by Region, 2016-2024 (USD Million)
Table 14 Global Microbubbles/Ultrasound Contrast Agents Market Size for Other therapeutic Areas, by Region, 2016-2024 (USD Million)
Table 15 Global Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
Table 16 Production of Microbubbles for Molecular Imaging
Table 17 Global Microbubbles/Ultrasound Contrast Agents Market Size for Molecular Imaging, by Region, 2016-2024 (USD Million)
Table 18 Global Microbubbles/Ultrasound Contrast Agents Market Size for Gene therapy, by Region, 2016-2024 (USD Million)
Table 19 Global Microbubbles/Ultrasound Contrast Agents Market Size for Drug Delivery, by Region, 2016-2024 (USD Million)
Table 20 Global Microbubbles/Ultrasound Contrast Agents Market Size for Stem Cell Delivery, by Region, 2016-2024 (USD Million)
Table 21 Global Microbubbles/Ultrasound Contrast Agents Market Size, by Region, 2018-2024 (USD Million)
Table 22 North America: Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
Table 23 North America: Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
Table 24 Europe: Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
Table 25 Europe: Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
Table 26 Asia-Pacific: Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
Table 27 Asia-Pacific: Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
Table 28 RoW: Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
Table 29 RoW: Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
List of Figures
Figure 1 Market Ecosystem
Figure 2 Key Stakeholders
Figure 3 Research Process
Figure 4 Key Executives interviewed
Figure 5 Primary Research Techniques
Figure 6 Key Opportunity
Figure 7 Molecular Imaging Dominates the Global Microbubbles/Ultrasound Contrast Agents Market
Figure 8 Microbubbles/Ultrasound Contrast Agents Market overview: 2018-2024
Figure 9 Global Microbubbles/Ultrasound Contrast Agents Market by Geography, 2017
Figure 10 Worldwide Cost of Operations in 2013 (In Euro)
Figure 11 Proportion of Aged Population in the World, 2010-2016 (% of total Population)
Figure 12 Older Population Aged 60 Years or over in the World (In Million), 1950-2050
Figure 13 Top Countries Facing Greatest Skills Shortage in 2014 (In %)
Figure 14 Global Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2018-2024 (USD Million)
Figure 15 Global Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2018-2024 (USD Million)
Figure 16 Global Microbubbles/Ultrasound Contrast Agents Market Size, by Geography, 2018-2024 (USD Million)
Figure 17 Number of Aged Population (Over 65) in U.S., 2000-2050 (In Million)
Figure 18 Share of total Alzheimer’s Dementia Cases in U.S., by Age Group, 2017
Figure 19 Proportion of Canadians Aged 65 and Older with Major Chronic Diseases, 2014
Figure 20 Proportion of Aged Population (65 and over) in EU Countries, 2010-2016 (% of total Population)
Figure 21 Population Aged 65 and over by Region, 2015-2050
Figure 22 New Cases of Cardiovascular Diseases, 1990-2015 (In Million)
Figure 23 Proportion of Population Aged 65 and over in Asia-Pacific Countries, 2010-2016 (% of total Population)
Figure 24 Proportional Mortality in China by therapeutic Area, 2011
Figure 25 Proportion of Population Aged 65 and over in Latin American Countries, 2010-2016 (% of total Population)
Figure 26 Proportion of Population Aged 65 and over in Middle East and African Countries, 2010-2016 (% of total Population)
Figure 27 Reported Mortality by Non-Communicable Diseases in Africa, 2013 (In %)
Figure 28 GRoWth Strategies Adopted by the Key Players
Figure 29 Lantheus Holdings, Inc.: Financial overview (2014-2016)
Figure 30 Bracco: Financial overview (2016)
Figure 31 GE Healthcare: Financial overview (2014-2016)
Figure 32 Daiichi Sankyo Company, Limited: Financial overview (2014-2016)
COVID-19
We are in the phase of updating this report by analysing the impact of COVID-19 on this market.
